CoChat

Prevention, screening, and treatment for heavy drinking and alcohol use disorder

Open access
Knox, Justin, Hasin, Deborah S, Larson, Farren R R, Kranzler, Henry R · 2019 · The Lancet Psychiatry
Cited by 141

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

Summary Heavy drinking and alcohol use disorder (AUD) are major public health problems. Practitioners not specializing in alcohol treatment are often unaware of the guidelines for preventing, identifying, and treating heavy drinking and AUD. However, a consensus exists that clinically useful and valuable tools are available to address these issues. Here, we provide a critical review of existing information and recent developments in these areas. We also include information on heavy drinking and AUD among individuals with co-occurring psychiatric disorders, including drug use disorders. Areas covered include prevention; screening, brief intervention, and referral for treatment (SBIRT); evidence-based behavioral interventions; medication-assisted treatment; technology-based interventions (eHealth and mHealth); and population-level interventions. We also discuss the key issues that remain for future research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(19)30213-5

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Research works printed but not linked: 94

  1. 2018, Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 392, 1015, 10.1016/S0140-6736(18)31310-2 · DOI · Paper page
  2. Parker, 2008, Diagnosis and management of alcohol use disorders, BMJ, 336, 496, 10.1136/bmj.39483.457708.80 · DOI
  3. Saunders, 2017, Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11, Curr Opin Psychiatry, 30, 227, 10.1097/YCO.0000000000000332 · DOI · Paper page
  4. Saunders, 2018, Alcohol use disorders in the draft ICD-11, and how they compare with DSM-5, Current Addiction Reports, 5, 257, 10.1007/s40429-018-0197-8 · DOI
  5. Hasin, 2017, Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population, Lancet Psychiatry, 4, 469, 10.1016/S2215-0366(17)30130-X · DOI · Paper page
  6. Rehm, 2003, Alcohol-related morbidity and mortality, Alcohol Res Health, 27, 39
  7. Rehm, 1996, Alcohol and all-cause mortality, Int J Epidemiol, 25, 215, 10.1093/ije/25.1.215 · doi:10.1093/ije/25.1.215
  8. Lewis-Laietmark, 2017, The effects of alcohol-related harms to others on self-perceived mental well-being in a Canadian sample, Int J Public Health, 62, 669, 10.1007/s00038-016-0924-7 · DOI
  9. Greenfield, 2015, Trends in alcohol's harms to others (AHTO) and co-occurrence of family-related AHTO: the four US national alcohol surveys, 2000–2015, Subst Abuse, 9, 23
  10. Cohen, 2007, Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions, Drug Alcohol Depend, 86, 214, 10.1016/j.drugalcdep.2006.06.008 · DOI · Paper page
  11. Shield, 2014, The potential impact of increased treatment rates for alcohol dependence in the United Kingdom in 2004, BMC Health Serv Res, 14, 53, 10.1186/1472-6963-14-53 · DOI · Paper page
  12. Lim, 2012, A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2224, 10.1016/S0140-6736(12)61766-8 · DOI · Paper page
  13. Stigler, 2011, School-based programs to prevent and reduce alcohol use among youth, Alcohol Res Health, 34, 157
  14. Martineau, 2013, Population-level interventions to reduce alcohol-related harm: an overview of systematic reviews, Prev Med, 57, 278, 10.1016/j.ypmed.2013.06.019 · DOI · Paper page
  15. Burton, 2017, A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective, Lancet, 389, 1558, 10.1016/S0140-6736(16)32420-5 · DOI · Paper page
  16. Watkins, 2017, Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial, JAMA Intern Med, 177, 1480, 10.1001/jamainternmed.2017.3947 · DOI · Paper page
  17. Willenbring, 2009, Helping patients who drink too much: an evidence-based guide for primary care clinicians, Am Fam Physician, 80, 44
  18. Curry, 2018, Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement, JAMA, 320, 1899, 10.1001/jama.2018.16789 · DOI · Paper page
  19. Whitlock, 2004, Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the US Preventive Services Task Force, Ann Intern Med, 140, 557, 10.7326/0003-4819-140-7-200404060-00017 · DOI · Paper page
  20. Chi, 2017, Alcohol brief intervention in primary care: blood pressure outcomes in hypertensive patients, J Subst Abuse Treat, 77, 45, 10.1016/j.jsat.2017.03.009 · DOI
  21. Ray, 2019, State-of-the-art behavioral and pharmacological treatments for alcohol use disorder, Am J Drug Alcohol Abuse, 45, 124, 10.1080/00952990.2018.1528265 · DOI · Paper page
  22. Pringle, 2012, Equipping residents to address alcohol and drug abuse: the national SBIRT residency training project, J Grad Med Educ, 4, 58, 10.4300/JGME-D-11-00019.1 · DOI
  23. Keyes, 2010, Stigma and treatment for alcohol disorders in the United States, Am J Epidemiol, 172, 1364, 10.1093/aje/kwq304 · DOI · Paper page
  24. Probst, 2015, Transition probabilities for four states of alcohol use in adolescence and young adulthood: what factors matter when?, Addiction, 110, 1272, 10.1111/add.12985 · DOI
  25. McKnight-Eily, 2014, Vital signs: communication between health professionals and their patients about alcohol use, 44 states and the District of Columbia, 2011, MMWR Morb Mortal Wkly Rep, 63, 16
  26. Bradley, 2011, Quality concerns with routine alcohol screening in VA clinical settings, J Gen Intern Med, 26, 299, 10.1007/s11606-010-1509-4 · DOI
  27. Bradley, 2006, Implementation of evidence-based alcohol screening in the Veterans Health Administration, Am J Manag Care, 12, 597
  28. Makdissi, 2013, Care for hospitalized patients with unhealthy alcohol use: a narrative review, Addict Sci Clin Pract, 8, 11, 10.1186/1940-0640-8-11 · DOI
  29. Palmer, 2019, Barriers faced by physicians in screening for substance use disorders among adolescents, Psychiatr Serv, 70, 409, 10.1176/appi.ps.201800427 · DOI
  30. Satre, 2008, Computerized screening for alcohol and drug use among adults seeking outpatient psychiatric services, Psychiatr Serv, 59, 441, 10.1176/ps.2008.59.4.441 · doi:10.1176/ps.2008.59.4.441
  31. Higgins, 1999, Contingency management: incentives for sobriety, Alcohol Res Health, 23, 122
  32. Petry, 2000, Give them prizes, and they will come: contingency management for treatment of alcohol dependence, J Consult Clin Psychol, 68, 250, 10.1037/0022-006X.68.2.250 · DOI · Paper page
  33. 1998, Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes, Alcohol Clin Exp Res, 22, 1300
  34. 1998, Matching alcoholism treatments to client heterogeneity: treatment main effects and matching effects on drinking during treatment, J Stud Alcohol, 59, 631, 10.15288/jsa.1998.59.631 · DOI · Paper page
  35. Lenaerts, 2014, Continuing care for patients with alcohol use disorders: a systematic review, Drug Alcohol Depend, 135, 9, 10.1016/j.drugalcdep.2013.10.030 · DOI
  36. Foxcroft, 2016, Motivational interviewing for the prevention of alcohol misuse in young adults, Cochrane Database Syst Rev, 7
  37. Gaume, 2009, Counselor skill influences outcomes of brief motivational interventions, J Subst Abuse Treat, 37, 151, 10.1016/j.jsat.2008.12.001 · DOI
  38. Bertholet, 2014, Do brief alcohol motivational interventions work like we think they do?, Alcohol Clin Exp Res, 38, 853, 10.1111/acer.12274 · DOI
  39. Wu, 2016, Cognitive behavioral therapy and motivational enhancement therapy, Child Adolesc Psychiatr Clin N Am, 25, 629, 10.1016/j.chc.2016.06.002 · DOI
  40. Carroll, 2004, Behavioral therapies for co-occurring substance use and mood disorders, Biol Psychiatry, 56, 778, 10.1016/j.biopsych.2004.07.010 · DOI
  41. Kelly, 2012, Treatment of substance abusing patients with comorbid psychiatric disorders, Addict Behav, 37, 11, 10.1016/j.addbeh.2011.09.010 · DOI · Paper page
  42. Garbutt, 2005, Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial, JAMA, 293, 1617, 10.1001/jama.293.13.1617 · DOI · Paper page
  43. Rosner, 2010, Acamprosate for alcohol dependence, Cochrane Database Syst Rev, 8
  44. Pierce, 2018, Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis, Eur Neuropsychopharmacol, 28, 795, 10.1016/j.euroneuro.2018.03.017 · DOI · Paper page
  45. Blodgett, 2014, A meta-analysis of topiramate's effects for individuals with alcohol use disorders, Alcohol Clin Exp Res, 38, 1481, 10.1111/acer.12411 · DOI · Paper page
  46. Knapp, 2015, Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders, J Clin Psychopharmacol, 35, 34, 10.1097/JCP.0000000000000246 · DOI · Paper page
  47. Froehlich, 2016, Combining varenicline (Chantix) with naltrexone decreases alcohol drinking more effectively than does either drug alone in a rodent model of alcoholism, Alcohol Clin Exp Res, 40, 1961, 10.1111/acer.13157 · DOI
  48. Erwin, 2014, Varenicline in the treatment of alcohol use disorders, Ann Pharmacother, 48, 1445, 10.1177/1060028014545806 · DOI
  49. Lynch, 2011, Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse, Psychopharmacology (Berl), 217, 3, 10.1007/s00213-011-2253-0 · DOI · Paper page
  50. Moore, 2014, Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats, Exp Clin Psychopharmacol, 22, 35, 10.1037/a0035215 · DOI
  51. Johnson, 2000, Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial, JAMA, 284, 963, 10.1001/jama.284.8.963 · DOI · Paper page
  52. Kranzler, 2003, Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study, Alcohol Clin Exp Res, 27, 1150, 10.1097/01.ALC.0000075547.77464.76 · DOI
  53. Kishi, 2013, Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials, J Clin Psychiatry, 74, e642, 10.4088/JCP.12r08178 · DOI
  54. Guardia, 2011, A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients, Addict Behav, 36, 265, 10.1016/j.addbeh.2010.11.006 · DOI
  55. Nunes, 2004, Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis, JAMA, 291, 1887, 10.1001/jama.291.15.1887 · DOI · Paper page
  56. Soyka, 2017, Pharmacotherapy of alcoholism: an update on approved and off-label medications, Expert Opin Pharmacother, 18, 1187, 10.1080/14656566.2017.1349098 · DOI · Paper page
  57. Krampe, 2006, Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome, Alcohol Clin Exp Res, 30, 86, 10.1111/j.1530-0277.2006.00013.x · DOI
  58. Soyka, 2017, Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision, World J Biol Psychiatry, 18, 86, 10.1080/15622975.2016.1246752 · DOI
  59. Brewer, 2017, Supervised disulfiram's superior effectiveness in alcoholism treatment: ethical, methodological, and psychological aspects, Alcohol Alcohol, 52, 213
  60. O’Malley, 1992, Naltrexone and coping skills therapy for alcohol dependence: a controlled study, Arch Gen Psychiatry, 49, 881, 10.1001/archpsyc.1992.01820110045007 · DOI · Paper page
  61. Mark, 2009, Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty, Drug Alcohol Depend, 99, 345, 10.1016/j.drugalcdep.2008.07.018 · DOI · Paper page
  62. Ponce Martinez, 2016, Pharmacotherapy for alcohol use disorders: physicians’ perceptions and practices, Front Psychiatry, 7, 182, 10.3389/fpsyt.2016.00182 · DOI
  63. Harris, 2013, Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers, Psychol Serv, 10, 410, 10.1037/a0030949 · DOI
  64. Kranzler, 2004, Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial, Alcohol Clin Exp Res, 28, 1051, 10.1097/01.ALC.0000130804.08397.29 · DOI · Paper page
  65. Edelman, 2019, Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: a randomized-controlled trial, AIDS Behav, 23, 211, 10.1007/s10461-018-2241-z · DOI
  66. Springer, 2017, Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community, Drug Alcohol Depend, 174, 158, 10.1016/j.drugalcdep.2017.01.026 · DOI
  67. Crits-Christoph, 2015, Extended-release naltrexone for alcohol and opioid problems in Missouri parolees and probationers, J Subst Abuse Treat, 56, 54, 10.1016/j.jsat.2015.03.003 · DOI
  68. Kalk, 2014, The clinical pharmacology of acamprosate, Br J Clin Pharmacol, 77, 315, 10.1111/bcp.12070 · DOI
  69. Paille, 2014, Nalmefene: a new approach to the treatment of alcohol dependence, Subst Abuse Rehabil, 5, 87, 10.2147/SAR.S45666 · DOI
  70. Litten, 2016, Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety, Subst Abus, 37, 286, 10.1080/08897077.2015.1133472 · DOI · Paper page
  71. Ducharme, 2006, Trends in the adoption of medications for alcohol dependence, J Clin Psychopharmacol, 26, S13, 10.1097/01.jcp.0000246209.18777.14 · DOI
  72. Knudsen, 2016, Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: data from a national sample of treatment organizations, Subst Abus, 37, 230, 10.1080/08897077.2015.1028699 · DOI
  73. Knudsen, 2014, The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources, J Stud Alcohol Drugs, 75, 476, 10.15288/jsad.2014.75.476 · DOI
  74. Anton, 2012, The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders, Neuropsychopharmacology, 37, 402, 10.1038/npp.2011.182 · DOI
  75. Witkiewitz, 2015, Recommendations for the design and analysis of treatment trials for alcohol use disorders, Alcohol Clin Exp Res, 39, 1557, 10.1111/acer.12800 · DOI · Paper page
  76. DeMartini, 2014, Predictors of pretreatment commitment to abstinence: results from the COMBINE study, J Stud Alcohol Drugs, 75, 438, 10.15288/jsad.2014.75.438 · DOI
  77. Maisto, 2018, Course of remission from and relapse to heavy drinking following outpatient treatment of alcohol use disorder, Drug Alcohol Depend, 187, 319, 10.1016/j.drugalcdep.2018.03.011 · DOI
  78. Mann, 2017, Can reduced drinking be a viable goal for alcohol dependent patients?, World Psychiatry, 16, 325, 10.1002/wps.20476 · DOI
  79. Meredith, 2015, Smartphone applications to reduce alcohol consumption and help patients with alcohol use disorder: a state-of-the-art review, Adv Health Care Technol, 1, 47
  80. Tofighi, 2018, The role of technology-based interventions for substance use disorders in primary care: a review of the literature, Med Clin North Am, 102, 715, 10.1016/j.mcna.2018.02.011 · DOI
  81. Nesvag, 2018, Feasibility and effects of digital interventions to support people in recovery from substance use disorders: systematic review, J Med Internet Res, 20, 10.2196/jmir.9873 · DOI · Paper page
  82. Naslund, 2017, Digital technology for treating and preventing mental disorders in low-income and middle-income countries: a narrative review of the literature, Lancet Psychiatry, 4, 486, 10.1016/S2215-0366(17)30096-2 · DOI · Paper page
  83. Dennis, 2015, A pilot study to examine the feasibility and potential effectiveness of using smartphones to provide recovery support for adolescents, Subst Abus, 36, 486, 10.1080/08897077.2014.970323 · DOI · Paper page
  84. Aharonovich, 2017, HealthCall delivered via smartphone to reduce co-occurring drug and alcohol use in HIV-infected adults: a randomized pilot trial, J Subst Abuse Treat, 83, 15, 10.1016/j.jsat.2017.09.013 · DOI
  85. Hasin, 2013, Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement, Addiction, 108, 1230, 10.1111/add.12127 · DOI
  86. Muroff, 2017, Use of a smartphone recovery tool for Latinos with co-occurring alcohol and other drug disorders and mental disorders, J Dual Diagn, 13, 280, 10.1080/15504263.2017.1348649 · DOI
  87. Kazemi, 2017, A systematic review of the mHealth interventions to prevent alcohol and substance abuse, J Health Commun, 22, 413, 10.1080/10810730.2017.1303556 · DOI · Paper page
  88. Fell, 2014, The effectiveness of a 0?05 blood alcohol concentration (BAC) limit for driving in the United States, Addiction, 109, 869, 10.1111/add.12365 · doi:10.1111/add.12365
  89. Elder, 2010, The effectiveness of tax policy interventions for reducing excessive alcohol consumption and related harms, Am J Prev Med, 38, 217, 10.1016/j.amepre.2009.11.005 · DOI · Paper page
  90. Wagenaar, 2010, Effects of alcohol tax and price policies on morbidity and mortality: a systematic review, Am J Public Health, 100, 2270, 10.2105/AJPH.2009.186007 · DOI · Paper page
  91. Warren, 2015, A review of the history of attitudes toward drinking in pregnancy, Alcohol Clin Exp Res, 39, 1110, 10.1111/acer.12757 · DOI
  92. Casswell, 2009, Reducing harm from alcohol: call to action, Lancet, 373, 2247, 10.1016/S0140-6736(09)60745-5 · DOI · Paper page
  93. Mann, 2018, Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes, Neuropsychopharmacology, 43, 891, 10.1038/npp.2017.282 · DOI
  94. Kranzler, 2014, Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism, Am J Psychiatry, 171, 445, 10.1176/appi.ajp.2013.13081014 · DOI · Paper page

Cited by

See all 141

Metadata

Authors
Knox, J., Hasin, D. S., Larson, F. R. R., & Kranzler, H. R.
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2019-12
Volume
6
Issue
12
Pages
1054-1067
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2980844170
Cited by
141
References
72
FWCI
8.61
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • New York State Psychiatric Institute
  • U.S. Department of Veterans Affairs
  • National Institute on Alcohol Abuse and Alcoholism (R01AA021164, R01AA023192, R01AA025309)
  • National Institute on Drug Abuse (T32DA031099)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention, screening, and treatment for heavy drinking and alcohol use disorder. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30213-5
The paper
Knox, J., Hasin, D. S., Larson, F. R. R., & Kranzler, H. R. (2019). Prevention, screening, and treatment for heavy drinking and alcohol use disorder. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30213-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.